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Background: Hepatocyte growth factor plays an important role in tumor growth, metastasis
and angiogenesis. C-met is HGF’s high afﬁnity receptor.
Aim: The aim of the study was to assess the correlations between c-met expression and
clinic-pathological factors in breast cancer tissues. Furthermore, the purpose of the study
was to evaluate the prognostic value of the hepatocyte growth factor receptor (HGFR, c-met)
expressions in homogenous group of breast cancer patients.
Materials and methods: Tumor samples were collected from 302 patients with breast
carcinoma treated with primary surgery. We have assessed the percentage of tumor
cells with c-met expression, the intensity of reaction and the ratio of these two
factors—immunoreactivity according to the Remmele score.
Results: We have observed no correlations between HGFR immunoreactivities and clinical
parameters (tumor size, grade, axillary lymph node status, age). In 5-year observation wehave found prognostic value of assessing c-met immunoreactivity in primary tumor.
Conclusion:Our studyhas revealedprognostic valueof c-met.Unlike inother authors’ studies,
our patients’ group is very homogenous which might contribute to obtained results.
© 2011 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.
z.o.o. All rights reserved.
tor. Hypoxia promotes HGF’s anti-apoptosis, invasion and. Introduction
n breast cancer patients, tumor size and lymph node stage
re two main prognostic factors.1 As a standard, the patient’s
ge, cancer histological type, its malignancy grade, steroid
eceptor expression and expression of HER-2 receptor are
ncluded in the group of prognostic factors.2 The detection of
elected immunohistochemical markers combined with the
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oi:10.1016/j.rpor.2011.04.001assessment of some pathoclinical features may separate the
subgroup of patients with favorable prognosis.3
Hepatocyte growth factor (HGF) is a cytokine that plays
an important role in tumor growth, invasion, metastasis
and angiogenesis and c-met is HGF’s high afﬁnity recep-2, 53-413Wrocław, Poland. Tel.: +48 665878752; fax: +48 713619111.
metastasis activities via HIF-1.4 Furthermore, c-met sig-
naling is involved in the regulation of tumor angiogenesis,
either directly through the proangiogenic activity of HGF that
. Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.
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Fig. 1 – The pattern of activation of hepatocyte growth
Fig. 2 – Immunohistochemical reaction with c-met
antibody IRS=12.factor.
induces formation of new vessels and sprouting of the pre-
existing ones or indirectly through the regulated secretion of
angiogenic factors.5
The c-met receptor is expressed selectively in several nor-
mal human epithelial tissues as well as in carcinoma. The
c-met encoded receptor is a 190-kilodalton (kDa) glycopro-
tein comprised of a transmembrane 145-kDa  subunit and
an extracellular 50-kDa  subunit and belongs to the tyrosine
kinase family of receptors.6
Several studies have shown that c-met has a prognostic
role in breast cancer patients but their results are contradic-
tory. The aim of this study was to assess the prognostic value
of determining the c-met immunoreactivity in breast cancer
tissue.
2. Materials and methods
Expression of c-met in 302 archival breast carcinoma spec-
imens from patients with invasive breast carcinoma was
evaluated using a standard immunoperoxidase technique.
Formalin-ﬁxed parafﬁn embedded, freshly cut 4m tissue
sections were mounted on Superfrost slides (Menzel Glaeser,
Germany), dewaxed with xylene, and gradually rehydrated.
The sections were incubated with citrate buffer at 98 ◦C to
unmask the epitopes and treated with 1% hydrogen per-
oxide (H2O2) for 10min to block endogenous peroxidase.
The sections were then incubated with human hepato-
cyte growth factor receptor mouse monoclonal antibody
(from Novocastra Laboratories Ltd.). The sections were fur-
ther incubated with biotin-labeled secondary antibody and
streptavidin–biotin–peroxidase for 20min each. The tissues
were stained for 5min with 0.05% 3.3′-diaminobenzidineFig. 3 – Correlation between c-met expression and OS.
tetrahydrochloride (DAB), counterstained with haematoxylin,
dehydrated and mounted (Figs. 1–3).
Each case was assessed by calculating the percentage of
cells with expression and intensity of reaction using the Rem-
mele score.7
The age of the patients at the diagnosis ranged from 29 to
83 years (median 57 years). According to TNM system, T1 was
recognized in 203 patients, T2 in 93 and higher stage of tumor
in 7. Axillary lymph node metastases were diagnosed in 126
patients.Histologically, 217 out of 302 tumorswere categorized
as inﬁltrating ductal carcinomas and 55 as inﬁltrating lobular
carcinomas. The expression of estrogen receptor was found in
193 patients and the expression of progesterone receptor was
found in 187 (Tables 1 and 2).
The univariate signiﬁcance of differences in the stud-
ied marker expressions was assessed by the chi-square test
for binary or categorical covariates, by the Pearson test and
by the Spearman rank correlation for ordered covariates.
Cancer-speciﬁc overall survival (OS) was estimated using the
Kaplan–Meier method, and the comparison between study
groups was performed with a log-rank test. The survival time
was measured from date of diagnosis to date of death or last
follow up. In all tests, the signiﬁcance level was set at 0.05 and
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Table 1 – Patients characteristics: stage of disease and G score.
pT stage pN stage Stage of disease G score
T1 198 (65.57%) N0 182 (60.27%) DCIS 3 (0.99%) G1 31 (10.27%)
T2 90 (29.80%) N1 54 (17.88%) I 131 (43.38%) G2 172 (56.95%)
T3 2 (0.66%) N2 42 (13.90%) IIA 75 (24.83%) G3 90 (29.80%)
T4 9 (2.98%) N3 24 (7.95%) IIB 21 (6.95%) Gx 9 (2.98%)
Tis 3 (0.99%) IIIA 41 (13.58%)
IIIB 6 (1.99%)
IIIC 25 (8.28%)
Table 2 – Patients characteristics: expression of hormonal and HER2/neu receptors according to Remmele score.
ER% ER I ER IRS PgR % PGR I PgR IRS HER2% HER2 I HER2 IRS
No assess. 5 5 5 5 5 5 21 21 21
0 106 106 106 111 111 111 53 53 53
1 32 37 21 35 20 10 18 76 15
2 44 126 29 38 114 30 24 96 13
3 77 28 1 63 52 7 74 56 30
4 38 – 24 50 – 21 112 – 34
6 – – 70 – – 56 – – 39
8 – – 21 – – 23 – – 42
9 – – 8 – – 13 – – 4
12 – – 17 – – 26 – – 51
Table 3 – The correlation between c-met expression and tumor size.
T1 vs T2 T1 vs T3 T1 vs T4 T2 vs T3 T2 vs T4 T3 vs T4
c-met % p=0.72 p=0.74 p=0.85 p=0.77 p=0.98 p=1
c-met I p=0.41 p=0.57 p=0.98 p=0.66 p=0.8 p=0.8
c-met IRS p=0.61 p=0.8 p=0.9 p=0.9 p=95 p=1
Table 4 – The correlation between c-met expression and lymph node status.
N0 vs N1 N0 vs N2 N0 vs N3 N1 vs N2 N1 vs N3 N2 vs N3 %N+
a
u
3
E
wc-met % p=0.78 p=0.67 p=0.65
c-met I p=0.54 p=0.87 p=0.45
c-met IRS p=0.22 p=0.056 p=0.35
ll were two-sided tests. Statistical analyses were performed
sing the R CRAN version 2.10 (http://cran.r-project.org).
. Resultsxpression of c-met was not shown in 3% of patients, in 70%
eak immunoreactionwas observed and 27%exhibited strong
Table 5 – The correlation between c-met expression and
stage of disease.
c-met % c-met I c-met IRS
I vs IIA p=0.3 p=0.91 p=0.4
I vs IIB p=0.87 p=0.77 p=0.9
I vs IIIA p=0.73 p=0.2 p=0.69
I vs IIIB p=0.42 p=0.56 p=0.53
I vs IIIC p=0.71 p=1 p=0.76
IIA vs IIB p=0.43 p=0.85 p=0.55
IIA vs IIIA p=0.55 p=0.34 p=0.3
IIA vs IIIB p=0.65 p=0.62 p=0.83
IIA vs IIIC p=0.34 p=0.96 p=0.45
IIB vs IIIA p=0.71 p=0.6 p=0.89
IIB vs IIIB p=0.41 p=0.55 p=0.56
IIB vs IIIC p=0.91 p=0.83 p=0.94
IIIA vs IIIB p=0.46 p=0.25 p=0.44
IIIA vs IIIC p=0.59 p=0.37 p=0.94
IIIB vs IIIC p=0.4 p=0.64 p=0.55p=0.24 p=0.68 p=0.76 p=0.43
p=0.34 p=0.67 p=0.23 p=0.35
p=0.64 p=1 p=0.7 p=0.36
immunoreaction. There was no correlation between c-met
expressionand tumor size, lymphnode status, stageof disease
or histological type of carcinoma. Moreover, we did not ﬁnd
any relations between the expression of hormone receptors,
HER2/neu and c-met. Details are shown in Tables 3–6.
The correlation between c-met expression and patients’ 5-
year overall survival established by the Kaplan–Meier method
showed increased survival in patients with a high marker
expression (p=0.0089).
Furthermore, the multivariate analysis revealed that pT
(p<0.0001), stage (p=0.041) and the expression of c-met
(p=0.013) were independent prognostic factors.
4. DiscussionIn the majority of tumors deriving from epithelium, c-met
overexpression is observed in the cytoplasm of cancer cells.
Table 6 – The correlation between c-met expression and
expression of hormonal and HER2/neu receptors.
ER PgR HER2/neu
c-met % p=0.175 p=0.0357 p=0.588
c-met I p=0.139 p=0.377 p=0.89
c-met IRS p=0.0911 p=0.134 p=0.447
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In ductal carcinoma in situ (DCIS), Lindemann et al.8 observed
the expression of c-met in both cancer and normal breast tis-
sue. However, in the majority of histological specimens the
expression of c-met protein was more intense in cancer com-
pared to surrounding physiological mammary gland tissue,
though in the quarter of cases the activity level was equal in
both.
In the current study, the immunoreactivity for c-met pro-
tein was retrospectively evaluated in 302 patients, 3% of
whom did not stain for c-met protein, in 70.5% only weak
immunoreactivity was seen, and 26.5% showed a strong c-
met expression. Our results were similar to those achieved
by Lengyel et al.,9 who used the same scoring system, Rem-
mele, evaluating c-met expression. In the group of 40 patients
with breast cancer and axillary lymph node involvement,
they showed weak immunoreactivity for this protein in 69%
of patients and strong one in 31%. Camp et al.10 also eval-
uated the percentage of cells, as well as the intensity of
c-met immunoreactivity, however, they used a scale other
than Remmele. Their results were comparable with ours, as
25% and 75% of breast cancer tissues showed strong and
weak immunoreactivity for c-met protein, respectively. In
other reports describing the pattern of c-met expression in
breast cancer tissue, only the percentage of cells with positive
immunohistochemical staining for c-met was showed, and
multifaceted cut-off limitswereused.11,12 Immunohistochem-
ical staining of breast cancer tissues performed by Carracedo
et al.11 demonstrated the expression of HGF’s receptor in only
insigniﬁcant percentage of patients (65/168). In this study, the
c-met receptor expressionwas observed slightlymore often in
the group of preinvasive cancers. Ghoussoub et al.13 divided
patients with breast cancer only into two groups: those with
weak c-met expression (immunoreactivity for c-met expres-
sion detected in less than 30% of cells) and strong c-met
expression (more than 70% found positive for c-met protein)
and compared them.
Other authors evaluating c-met expression in head and
neck,5,14 lung,15 and esophagus cancer,4 examined only the
percentage of cells stained and assumed different values for
the intensity of c-met immunoreactivity.
The chosenmethod of immunoreactivity scoring and anal-
ysis for c-met in breast cancer tissue by assessing both the
percentage of stained cells and the intensity of expression in
accordance with the Remmele scoring system is very precise.
It also provides much more information about the pattern of
immunoreactivity. However, it limits the possibility of com-
paring our results with those yielded by other authors, as few
evaluated both the percentage of stained cells and the inten-
sity of expression.
In our study, we did not ﬁnd any relation between c-
met expression and tumor size, lymph node status, stage of
disease or histological type of carcinoma. Most researchers
have not found any relationship between the intensity of
c-met expression and the acknowledged prognostic factors,
such as tumor size, lymph nodes status or hormonal receptor
expression.10,13,16–19 However, in a small group of 31 patients
with invasive breast cancer, Greenberg et al.12 demonstrated
a correlation between the intensity of c-met expression and
tumor size: expression was observed in all tumors with
more than 2 cm of diameter, whereas in only 50% of casesiotherapy 1 6 ( 2 0 1 1 ) 173–177
when tumor size was less than 1 cm in diameter. In patients
with axillary lymph nodes metastases, c-met expression was
observed in all specimens. However, only half of the patients
with axillary lymph node involvement presented c-met posi-
tive staining.
Moreover,wedidnot ﬁndany relations between the expres-
sion of hormone receptors, HER2/neu and c-met. Lindemann
et al.8 also did not observe the correlation between c-met and
Her2/neu expression. In a considerably larger group of 200
patients diagnosed with DCIS, Gotte et al.5 showed a strong
correlation between the intensity of c-met and Her2/neu
receptor expression. Carracedo et al.11 demonstrated that c-
met expression positively correlated with estrogen receptor
expression and negatively with progesterone receptor expres-
sion.
The prognostic value of c-met expression was conﬁrmed:
signiﬁcantly better survival was observed in patients with
overexpression of this marker. This is in accordance with
results yielded by Nakopoluou et al.,20 as he also showed
better survival for patients with strong immunoreactivity for
c-met. In opposition to our results stand other reports in
which overexpression of c-met was associated with worse
prognosis in patients with breast cancer. Ghoussoub et al.13
found a signiﬁcant negative association between the c-
met staining intensity and 5- and 10-year survival among
patients with invasive breast cancer, the predictive value
of this parameter was showed to be nearly equivalent to
lymph node status. In a group of patients with invasive
breast cancer without nodal involvement. In Lengyel et al.9
study overexpression of c-met was a statistically signiﬁ-
cant adverse prognostic factor (p=0.045); 5 years DFS was
30% in patients with overexpression and 54% in those with
weak staining for c-met, respectively. Camp et al.10 showed
a decreased 5-year overall survival in patients with over-
expression of c-met. Similar results were yielded by Parr
et al.,19 who described a worse prognosis in patients with
invasive breast cancer and overexperssion of c-met, during a
median follow-up of 6 years. In unison with above mentioned
reports, Ocal et al.18 described, based on 10-year follow-up, a
worse prognosis in breast cancer patientswith overexpression
of c-met.
We could not compare directly the results of above-
mentioned authors with ours because of the large differences
in study methodologies. As far as patients are concerned, our
sample is the biggest; compared with 40 patients in Lengyel
et al.,9 113 patients in Camp et al.10 and 91 in Ghoussoub
et al.13 Furthermore, Ghoussoub et al.13 divided their mate-
rial in two subgroups: cases with <20–30% positive or >70–80%
positive expressions of c-met; however, this division could
not be accurate and univocal as the subgroup with 30% to
70% of cells with c-met positive reactivity may be assigned
to both subgroups. On the other hand, in Camp et al.10
H-score was calculating by assessing the immunoreactivity
of c-met in tumor and this score could not be compared
with the Remmele score. In Lengyel et al.,9 the reactivity
of c-met was assessed both in cells cytoplasm and cells
membrane. For those reasons, we could not compare our
results with other research works and further studies must
be conducted to conﬁrm the prognostic signiﬁcance of c-met
expression.
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. Conclusion
he expression of c-met in patients with invasive carcinoma
f the breast is a strong, independent prognostic factor. It may
e useful to identify a subset of patients with less aggressive
isease.
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